Evaluating the effectiveness of targeted therapy and sbrt in athletic patients with egfr-mutated nsclc

Abstract

Objective: This study aims to assess the efficacy and safety of combining targeted therapy with stereotactic body radiotherapy (SBRT) in treating athletic patients with EGFR-mutated non-small cell lung cancer (NSCLC). Methods: Forty-two athletic patients with advanced EGFR-mutated NSCLC, treated from January 2016 to December 2017, were prospectively enrolled and randomly assigned into two groups. Twenty-one patients received both targeted therapy and SBRT (combination therapy group), while the remaining 21 were treated with targeted therapy alone (single therapy group). Treatment efficacy was evaluated using the RECIST criteria, including lung function improvement post-treatment, progression-free survival (PFS), median survival, and the incidence of adverse reactions. Results: The disease control rate (DCR) in the combination therapy group was significantly higher at 80.95% compared to 52.38% in the single therapy group (P<0.05). Improvements in lung function parameters (FVC, FEV1, and PEF) were noted after four treatment cycles in both groups, with the combination group showing significantly better outcomes (P<0.05). Adverse reaction rates were comparable between groups. The combination therapy group also exhibited a significantly longer median PFS (P<0.05). Conclusion: The integration of targeted drugs with SBRT in treating athletic patients with EGFR-mutated NSCLC demonstrates significant clinical efficacy, improving survival rates without escalating adverse effects, underscoring its potential for broader clinical application.